Results 41 to 50 of about 3,595 (167)

Impact of first-line dalbavancin for cellulitis on hospital admissions and costs: A case series

Journal of Global Antimicrobial Resistance
Background: Many patients with cellulitis are treated with oral antibiotics as outpatients, but some require hospital admission for intravenous antibiotics.
Kailey Ben-Sassi, Suhail Sarwar
doaj   +1 more source

Determination of the Elution Capacity of Dalbavancin in Bone Cements: New Alternative for the Treatment of Biofilm-Related Peri-Prosthetic Joint Infections Based on an In Vitro Study

Antibiotics, 2022
Antibiotic-loaded bone cement is the most widely used approach for the treatment of biofilm-induced septic sequelae in orthopedic surgery. Dalbavancin is a lipoglycopeptide that acts against Gram-positive bacteria and has a long half-life, so we aimed to
Mar Sánchez-Somolinos, Marta Díaz-Navarro, Antonio Benjumea, Marta Tormo, José Matas, Javier Vaquero, Patricia Muñoz, Pablo Sanz-Ruíz, María Guembe   +8 more
doaj   +1 more source

Multidose Dalbavancin Population Pharmacokinetic Analysis for Prolonged Target Attainment in Patients Requiring Long-Term Treatment

Antibiotics
Introduction: Dalbavancin (DAL) is a long-acting lipoglycopeptide active against Gram-positive bacteria, including multidrug-resistant isolates. A growing body of evidence supports its efficacy in various difficult-to-treat infections.
Giammarco Baiardi, Michela Cameran Caviglia, Silvia Boni, A. di Paolo, Valeria Marini, G. Cangemi, A. Cafaro, E. Pontali, Francesca Mattioli   +8 more
semanticscholar   +1 more source

Saarvienin A—A Novel Glycopeptide with Potent Activity against Drug‐Resistant Bacteria

Angewandte Chemie, Volume 137, Issue 25, June 17, 2025.
A structurally distinct glycopeptide, saarvienin A, represents a new family of glycopeptide antibiotics consisting of five sugar/aminosugar units connected to a halogenated peptide core. Saarvienin A overcomes vancomycin resistance and shows strong activity against drug‐resistant Gram‐positive bacteria, in particular, high‐priority pathogens such as ...
Amninder Kaur, Jaime Felipe Guerrero‐Garzón, Sari Rasheed, Martin Zehl, Franziska Fries, Bernd Morgenstern, Sergey B. Zotchev, Rolf Müller   +7 more
wiley   +2 more sources

Real-world evidence of dalbavancin effectiveness as consolidation therapy in infective endocarditis due to Enterococcus spp.

Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi
Enterococcal endocarditis (EIE) affects elderly patients, with high rates of complications and mortality, and dalbavancin (DBV) exhibits significant antimicrobial activity against most enterococci. However, data are lacking on the use of DBV in EIE.
Carmen Hidalgo-Tenorio, Svetlana Sadyrvaeba-Dolgova, Eduardo Aparicio-Minguijón, Arístides Alarcón, Antonio Plata, F. J. Martínez Marcos, Beatriz Álvarez-Álvarez, Belén Loeches, B. Varisco, Agustín Estévez, C. Herrero, F. Escrihuela-Vidal, L. Boix-Palop, Yvon Ruch, F. Valour, Nahéma Issa, Pauline Thill, S. Nguyen, Samantha Poloni, Romain Millot, Nathan Peiffer-Smadja, Timothée Boyer-Chammard, K. Diallo, R. Larcher, J. Miró, D. L. Paz, Luis Eduardo López Cortés, A. Moreno, Sergio Sequera   +28 more
semanticscholar   +1 more source

Dalbavancin versus standard of care for the treatment of osteomyelitis in adults: A retrospective matched cohort study

Saudi Pharmaceutical Journal, 2020
Objective: To assess the safety and effectiveness of dalbavancin compared to standard of care (SOC) in the treatment of osteomyelitis in adults. Method: A retrospective cohort study of patients with osteomyelitis due to S. aureus treated with dalbavancin
Thamer A. Almangour, Gregory K. Perry, Abdullah A. Alhifany   +2 more
doaj   +1 more source

Efficacy of Novel Antimicrobial Therapies for Treating Staphylococcus Infections in Wistar Rats

مجلة الانبار للعلوم البيطرية
The novel semisynthetic lipoglycopeptide dalbavancin has enhanced antibacterial action against a wide range of gram-positive bacteria. This study was conducted to evaluate the efficacy of dalbavancin in treating Staphylococcus Infections in ...
Noman D. Salih.
doaj   +1 more source

Simultaneous Quantification and Pharmacokinetic Study of Five Homologs of Dalbavancin in Rat Plasma Using UHPLC-MS/MS

Molecules, 2020
Dalbavancin is a novel semisynthetic glycopeptide antibiotic that comprises multiple homologs and isomers of similar polarities. However, pharmacokinetic studies have only analyzed the primary components of dalbavancin, namely B0 and B1.
Difeng Zhu, Li Ping, Yawen Hong, Jiale Shen, Qinjie Weng, Qiaojun He   +5 more
doaj   +1 more source

The hidden cost of dalbavancin: OPAT RN time required in coordination for persons who use drugs

Therapeutic Advances in Infectious Disease, 2023
Background: Serious infections in persons who use drugs (PWUD) are rising. Dalbavancin, due to its extended half-life, offers an alternative treatment for patients in whom standard of care antibiotics are not feasible or practical, allowing for reduced ...
Alyse H. Douglass, Heather Mayer, Kathleen Young, Monica K. Sikka, Luke Strnad, Jina Makadia, Ellie Sukerman, James S. Lewis, Amber C. Streifel   +8 more
doaj   +1 more source

Long-Term Suppressive Therapeutic-Drug-Monitoring-Guided Dalbavancin Therapy for Cardiovascular Prosthetic Infections

Antibiotics, 2023
Dalbavancin represents a promising treatment for cardiovascular prosthetic infections due to its prolonged half-life, bactericidal activity, large spectrum of activity, and excellent biofilm penetration. However, the use of dalbavancin in this setting is
Altea Gallerani, Milo Gatti, Andrea Bedini, Stefania Casolari, Gabriella Orlando, Cinzia Puzzolante, Erica Franceschini, Marianna Menozzi, Antonella Santoro, Nicole Barp, Sara Volpi, Alessandra Soffritti, Federico Pea, Cristina Mussini, Marianna Meschiari   +14 more
doaj   +1 more source